ArticleFrontiers in neuroscience2026
Human P301L tau expression in mice alters neuronal excitability independent of neurodegeneration.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Variation in the microtubule-binding protein tau is causally implicated in numerous neurodegenerative diseases, including Alzheimer's disease. However, the mechanisms by which such variation results in disease are not well understood. The JNPL3(P301L) mouse model mimics the effects of the P301L mutation on human tau associated with frontotemporal dementia. As previously reported, phospho-tau aggregates immunolabeled with AT8 increase with age in a rostral progression from the brainstem; however, there is relatively limited forebrain pathology by the time these animals die prematurely at approximately 1 year of age. In this study, we investigated the functional effects of P301L tau expression on electrophysiological signatures as a function of age in mice expressing P301L tau from 3 to 10 months. The P301L mice had a distinct electrophysiological phenotype of increased power in higher EEG frequency bands detected with a depth electrode in the hippocampus and, to a lesser extent, with dural surface electrodes over the frontal and parietal cortices. Significantly, this electrophysiological phenotype was present at the first recording at 3 months of age and did not differ over monthly recordings up to 9 months of age, after which point animals became moribund and were euthanized. P301L mice at 10 months of age also showed electrical synchronization to a 40 Hz tone (ASSR) that was not observed in WT mice and an increase in inter-trial coherence compared with WT mice. We confirmed that AT8, as well as markers of neuroinflammation, increased progressively with age from the hindbrain to the forebrain, as previously reported. Together, these data suggest an increase in neuronal excitability in P301L mice compared with WT, but that this phenotype is not correlated with the age-dependent accumulation of AT8-labeled tau aggregates and the accompanying neuroinflammation. We hypothesize that the expression of P301L mutant tau disrupted the physiological functions of tau, resulting in the functional electrophysiological phenotype. Whether this functional effect drives neurodegeneration or is a separable phenomenon has implications for understanding the mechanisms underlying the role of tau variation in neurodegenerative conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.